#news #medical #clinicalresearch #lifesciences #pharma #pharmiweb
Graft-versus-host disease, Cytokine release syndrome, TGN1412, Anti-thymocyte globulin, Form 10-K, Cytokine
Humanigen Elects Dr. Dale Chappell to Board of Directors
Humanigen Elects Dr. Dale Chappell to Board of Directors
https://t.co/HbtRnWGLU4
#news #pharma #clinicalresearch #biotech #lifesciences #medical #healthcare #pharmiweb https://t.co/p1vUMz7YDq
OpenBURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (NASDAQ:HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate lenzilumab™, today announced that the Company’s Board ...
Humanigen Elects Dr. Dale Chappell to Board of Directors
https://t.co/HbtRnWGLU4
#news #pharma #clinicalresearch #biotech #lifesciences #medical #healthcare #pharmiweb https://t.co/p1vUMz7YDq
OpenHumanigen Elects Dr. Dale Chappell to Board of Directors
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (NASDAQ:HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response ...
We are sorry, we could not find the related article
If you are curious about Biotech Essentials, the Influencers Review and Career and Jobs
Please click on:
Or signup to our newsletters
Other Essentials
AI Essentials
Robotics
Robotics
Ethics
Ethics
Research
Research
Applied Use Cases
Applied Use Cases
Marketing
Marketing
Healthcare
Healthcare
Cybersecurity
Cybersecurity
Humanigen and Avid Bioservices Enter Into cGMP Manufacturing Agreement for COVID-19 Therapeutic Candidate Lenzilumab in Support of Potential EUA Filing
BURLINGAME, Calif. & TUSTIN, Calif. --(BUSINESS WIRE)--Feb. 3, 2021-- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP) (“Avid”) and Humanigen, Inc. (NASDAQ:HGEN) (“Humanigen”) today ...
CytoSorb® Assigned Dedicated Procedure Code in Switzerland
MONMOUTH JUNCTION, N.J., Sept. 20, 2018 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO) a critical care immunotherapy leader using its CytoSorb® bloo...
Humanigen momentum barges on as Covid-19 candidate is selected for NIAID trial
One of “Pharma Bro” Martin Shkreli’s former biotechs came back from the dead during the Covid-19 pandemic thanks to its drug candidate targeting cytokine storms. Now, that company has ...
A ‘Human’ Touch vs. COVID-19
Four years since its emergence from a bankruptcy, touched off by the arrest of its former CEO, “Pharma Bro” Martin Shkreli, Humanigen is testing whether its engineered antibody or ...
Equillium Announces Positive Interim Data with Itolizumab in Acute GVHD Study
Complete response observed in five of seven patients in first two dose cohorts COVID-19 Pre-IND meeting request and briefing package submitted to the FDA ...
Cytokine Storm
Review Article from The New England Journal of Medicine — Cytokine Storm
SYK inhibitor entospletinib prevents ocular and skin GVHD in mice
Scoring criteria were as follows: dermis (0, normal; 1, mild increased collagen density; 2, marked increased collagen density); hair follicles (0, normal number of approximately 5 per ...
Ruxolitinib shows promise in severe COVID-19
An anti-inflammatory drug Ruxolitinib has shown promising results in the treatment of severe coronavirus disease COVID-19. The study titled, “Ruxolitinib in treatment of severe coronavirus ...